Fourth Time Lucky: How Mithra’s Novel Estrogen E4 Is Disrupting The Women’s Health Market
CEO David Solomon Tells In Vivo About His Leadership Journey And Mithra's Plans For The Future
Podcast: Mithra is shaking up the stagnant women’s health market with a brand new estrogenic compound. E4, or estetrol, is a natural estrogen produced by the human fetus during pregnancy, and could represent a major breakthrough in contraceptive and menopause care.
You may also be interested in...
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.